TGR-1202 is an orally available, next generation PI3Kdelta inhibitor, inhibits PI3Kδ activity in enzyme and cell based assays with IC50 and EC50 values of 22.2 and 24.3 nM respectively.
Product Name: TGR-1202 |Catalog Number: DC8653 |CAS 1532533-67-7 |Other names: RP5264; TGR1202; TGR 1202; RP-5264; RP 5264 |Chemical Name: |Molecule Formular: C31H24F3N5O3 |MW: 571.55
in vitro: TGR-1202 displays a high degree of selectivity over the alpha (>1000 fold), beta (>30-50 fold), and gamma (>15-50 fold) isoforms. Additionally, TGR-1202 causes a half-maximal inhibition of human whole blood CD19 cell proliferation between 100-300 nM. Treatment of PBMC with RP5264 resulted initially in a G2/M arrest followed by subsequent increase in the number of Sub G0 cells. Viability assays demonstrated that TGR-1202 caused a significant inhibition in growth as well as Akt phosphorylation of immortalized and primary leukemic cells. Further, the compound exhibited good oral absorption with favourable pharmacokinetic properties in rodents.
For research and scientific purpose only, not for human use!
没有评论:
发表评论